Establishment and Validation of a Pseudovirus Neutralization Assay for SARS-CoV-2

Overview

Journal Emerg Microbes Infect

Specialty Infectious Diseases

Date 2020 Mar 25

PMID 32207377

Citations 452

Authors

Jianhui Nie

Qianqian Li

Jiajing Wu

Chenyan Zhao

Huan Hao

Huan Liu

Li Zhang

Lingling Nie

Haiyang Qin

Meng Wang

Qiong Lu

Xiaoyu Li

Qiyu Sun

Junkai Liu

Changfa Fan

Weijin Huang

Miao Xu

Youchun Wang

Affiliations

Soon will be listed here.

Abstract

Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.

Citing Articles

Construction of pseudotyped human coronaviruses and detection of pre-existing antibodies in the human population.

Jiang Q, Wu X, Dong F, Qiao S, Shi Q, Jian C Biosaf Health. 2025; 6(5):279-285.

PMID: 40078732 PMC: 11894997. DOI: 10.1016/j.bsheal.2024.09.002.

Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection.

Jung J, Sung J, Kwon S, Bae H, Kang M, Jose J RSC Med Chem. 2025; .

PMID: 39990164 PMC: 11843257. DOI: 10.1039/d4md00992d.

A Live-Cell Imaging-Based Fluorescent SARS-CoV-2 Neutralization Assay by Antibody-Mediated Blockage of Receptor Binding Domain-ACE2 Interaction.

Arias-Arias J, Monturiol-Gross L, Corrales-Aguilar E BioTech (Basel). 2025; 14(1).

PMID: 39982277 PMC: 11843899. DOI: 10.3390/biotech14010010.

A single mutation at position 214 of influenza B hemagglutinin enhances cross-neutralization.

Cheng Z, Sun Y, Shen Y, Wu X, Pan L, Wu H Emerg Microbes Infect. 2025; 14(1):2467770.

PMID: 39960410 PMC: 11849025. DOI: 10.1080/22221751.2025.2467770.

Characterization of spike S1/S2 processing and entry pathways of lentiviral pseudoviruses bearing seasonal human coronaviruses NL63, 229E, and HKU1 spikes.

Neerukonda S, Vassell R, Lusvarghi S, Liu S, Akue A, Kukuruga M Microbiol Spectr. 2025; 13(3):e0280824.

PMID: 39873512 PMC: 11878054. DOI: 10.1128/spectrum.02808-24.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

Phelan A, Katz R, Gostin L . The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020; 323(8):709-710. DOI: 10.1001/jama.2020.1097. View

Kuo C, Chiang A, Shamie I, Samoudi M, Gutierrez J, Lewis N . The emerging role of systems biology for engineering protein production in CHO cells. Curr Opin Biotechnol. 2017; 51:64-69. PMC: 5988649. DOI: 10.1016/j.copbio.2017.11.015. View

Li Q, Liu Q, Huang W, Wu J, Nie J, Wang M . An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. Vaccine. 2017; 35(38):5172-5178. DOI: 10.1016/j.vaccine.2017.07.101. View

Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, Krumbiegel M . S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol. 2004; 78(12):6134-42. PMC: 416513. DOI: 10.1128/JVI.78.12.6134-6142.2004. View

Nie J, Wu X, Ma J, Cao S, Huang W, Liu Q . Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017; 7:42769. PMC: 5316940. DOI: 10.1038/srep42769. View

Enjuanes L, Zuniga S, Castano-Rodriguez C, Gutierrez-Alvarez J, Canton J, Sola I . Molecular Basis of Coronavirus Virulence and Vaccine Development. Adv Virus Res. 2016; 96:245-286. PMC: 7112271. DOI: 10.1016/bs.aivir.2016.08.003. View

Whitt M . Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods. 2010; 169(2):365-74. PMC: 2956192. DOI: 10.1016/j.jviromet.2010.08.006. View

10.

Jiang S, He Y, Liu S . SARS vaccine development. Emerg Infect Dis. 2005; 11(7):1016-20. PMC: 3371787. DOI: 10.3201/1107.050219. View

11.

Nakamura K, Harada Y, Takahashi H, Trusheim H, Bernhard R, Hamamoto I . Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus. Vaccine. 2019; 37(43):6526-6534. DOI: 10.1016/j.vaccine.2019.08.064. View

12.

Li Q, Liu Q, Huang W, Li X, Wang Y . Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2017; 28(1). PMC: 7169153. DOI: 10.1002/rmv.1963. View

13.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

14.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

15.

Chen Q, Nie J, Huang W, Jiao Y, Li L, Zhang T . Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. Hum Vaccin Immunother. 2017; 14(1):199-208. PMC: 5791569. DOI: 10.1080/21645515.2017.1373922. View

16.

Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S . The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3):226-36. PMC: 2750777. DOI: 10.1038/nrmicro2090. View

17.

Liu Q, Fan C, Li Q, Zhou S, Huang W, Wang L . Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep. 2017; 7:45552. PMC: 5372081. DOI: 10.1038/srep45552. View

18.

Wu J, Zhao C, Liu Q, Huang W, Wang Y . Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system. Vaccine. 2017; 35(47):6387-6394. DOI: 10.1016/j.vaccine.2017.10.007. View

19.

Roper R, Rehm K . SARS vaccines: where are we?. Expert Rev Vaccines. 2009; 8(7):887-98. PMC: 7105754. DOI: 10.1586/erv.09.43. View

20.

Ma J, Chen R, Huang W, Nie J, Liu Q, Wang Y . and efficacy of a Rift Valley fever virus vaccine based on pseudovirus. Hum Vaccin Immunother. 2019; 15(10):2286-2294. PMC: 6816429. DOI: 10.1080/21645515.2019.1627820. View